Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
Status:
RECRUITING
Trial end date:
2028-09-15
Target enrollment:
Participant gender:
Summary
This study is a prospective, multicenter, single arm Phase II exploratory study. It is expected to include 24 first-line patients with small cell lung cancer who have progressed after 6 months of treatment with platinum containing regimens, and receive treatment with irinotecan liposomes combined with cisplatin or carboplatin regimens.